Fenchem is devoting to pet health with SAM-e expansion

07-02-2011 | |

Supplemental SAM-e has recently gained worldwide recognition for its efficacy on animals with liver or joint disease.

S-adenosylmethionine (SAM-E) is a substance produced by the body from the amino acid methionine. It is traditionally sold as a prescription drug in Europe, and however as dietary supplement in the US in the treatment of many conditions including depression, liver disease and osteoarthritis etc.
Fenchem’s SAMe-way is available in two salt forms, Ademetionine 1,4-Butanedisulfonate and Ademetionine Disulfate Tosylate.
One prominent advantage of SAMe-way is that the ratio of active ingredient (s,s) isomer is high up to more than 70%, which ensures high bioavailability and cost savings for customers.
With the booming demand of SAM-e in pet supplement industry, Fenchem is to optimize technology and cost saving, looking to expand the production capability in the coming year. More competitive pricing will be guaranteed with the production increase.
SAM-e is the ‘lynchpin’ of three major biochemical pathways (transmethylation, transsulfuration, and aminopropylation) which regulate or impact virtually every biochemical reaction in humans and animals.
Neurochemistry, liver biology, cartilage, bone and joint health, are just some of the realms heavily influenced by the efficiency of one’s SAM-e metabolism.
It has been clinically shown to have benefits on joint health, brain health, longevity and liver health.
Fenchem is specialized in developing, manufacturing and marketing active ingredients for dietary supplement and functional foods.
The products are manufactured adherence to premium quality that is guaranteed by practices of GMP, HACCP and ISO certification.

Dick Ziggers Former editor All About Feed

2/3 articles remaining | Register to continue reading.